ES2069761T3 - Composicion de trombina para la administracion oral. - Google Patents

Composicion de trombina para la administracion oral.

Info

Publication number
ES2069761T3
ES2069761T3 ES91103077T ES91103077T ES2069761T3 ES 2069761 T3 ES2069761 T3 ES 2069761T3 ES 91103077 T ES91103077 T ES 91103077T ES 91103077 T ES91103077 T ES 91103077T ES 2069761 T3 ES2069761 T3 ES 2069761T3
Authority
ES
Spain
Prior art keywords
composition
oral administration
thrombine
thrombin
excellent solubility
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91103077T
Other languages
English (en)
Inventor
Yasuyuki C O Mochida Kunihiro
Ryo C O Mochida Pharmac Tanaka
Seishichi C O Mochida Pha Hata
Koji C O Mochida Pharma Yamada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mochida Pharmaceutical Co Ltd
Original Assignee
Mochida Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mochida Pharmaceutical Co Ltd filed Critical Mochida Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2069761T3 publication Critical patent/ES2069761T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

UN COMPUESTO ESTABLE DE TROMBINA PARA ADMINISTRACION ORAL PROVISTO DE SOLUBILIDAD EXCELENTE SE PREPARA CON LA TROMBINA COMO INGREDIENTE HEMOSTATICO, GELATINA, ALBUMINA Y GLICINA COMO UN ESTABILIZADOR Y LA SACAROSA Y/O ALCOHOL DE AZUCAR COMO UN PORTADOR. EL COMPUESTO DE TROMBINA ES EFECTIVO PARA EL TRATAMIENTO DE LAS HEMORRAGIAS EN EL CANAL ALIMENTARIO SUPERIOR, ES ESTABLE AUN EN CONDICIONES DE TEMPERATURA DE HABITACION DURANTE LARGOS PERIODOS DE TIEMPO, POSEE SOLUBILIDAD EXCELENTE Y PUEDE ADMINISTRARSE ORALMENTE DE MANERA SENCILLA.
ES91103077T 1990-03-01 1991-03-01 Composicion de trombina para la administracion oral. Expired - Lifetime ES2069761T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2050494A JPH0813750B2 (ja) 1990-03-01 1990-03-01 経口用トロンビン製剤

Publications (1)

Publication Number Publication Date
ES2069761T3 true ES2069761T3 (es) 1995-05-16

Family

ID=12860487

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91103077T Expired - Lifetime ES2069761T3 (es) 1990-03-01 1991-03-01 Composicion de trombina para la administracion oral.

Country Status (9)

Country Link
US (1) US5149540A (es)
EP (1) EP0444692B1 (es)
JP (1) JPH0813750B2 (es)
AT (1) ATE116858T1 (es)
AU (1) AU643753B2 (es)
CA (1) CA2037325A1 (es)
DE (1) DE69106549T2 (es)
DK (1) DK0444692T3 (es)
ES (1) ES2069761T3 (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3942143A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh T-pa pro stabilisierung
DE3942141A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh K2p pro-stabilisierung
US5595735A (en) * 1990-05-23 1997-01-21 Johnson & Johnson Medical, Inc. Hemostatic thrombin paste composition
US6391343B1 (en) 1991-01-15 2002-05-21 Hemosphere, Inc. Fibrinogen-coated particles for therapeutic use
WO1996039128A1 (en) * 1995-06-06 1996-12-12 Hemosphere, Inc. Protein particles for therapeutic and diagnostic use
US5725804A (en) * 1991-01-15 1998-03-10 Hemosphere, Inc. Non-crosslinked protein particles for therapeutic and diagnostic use
US5616311A (en) * 1991-01-15 1997-04-01 Hemosphere, Inc. Non-crosslinked protein particles for therapeutic and diagnostic use
FR2679251B1 (fr) * 1991-07-18 1993-11-12 Nord Assoc Essor Transfusion San Procede de preparation d'un concentre de thrombine humaine destine a un usage therapeutique.
DE4137996A1 (de) * 1991-11-19 1993-05-27 Behringwerke Ag Verfahren zur herstellung eines virussicheren thrombinkonzentrates
US6017953A (en) * 1993-12-28 2000-01-25 Allergan Sales, Inc. Thromboxane ligands
US5506127A (en) * 1994-09-21 1996-04-09 Proba; Zbigniew Therapeutic grade thrombin produced by chromatography
DE19539574A1 (de) * 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
AU702955B2 (en) * 1996-05-17 1999-03-11 Quadrant Healthcare (Uk) Limited Microparticles and their use in wound therapy
US7435425B2 (en) * 2001-07-17 2008-10-14 Baxter International, Inc. Dry hemostatic compositions and methods for their preparation
US6063061A (en) * 1996-08-27 2000-05-16 Fusion Medical Technologies, Inc. Fragmented polymeric compositions and methods for their use
US8603511B2 (en) 1996-08-27 2013-12-10 Baxter International, Inc. Fragmented polymeric compositions and methods for their use
US7871637B2 (en) 1996-08-27 2011-01-18 Baxter International Inc. Dry hemostatic compositions and methods for their preparation
US8303981B2 (en) 1996-08-27 2012-11-06 Baxter International Inc. Fragmented polymeric compositions and methods for their use
US6066325A (en) 1996-08-27 2000-05-23 Fusion Medical Technologies, Inc. Fragmented polymeric compositions and methods for their use
US6264988B1 (en) 1997-06-05 2001-07-24 Hemosphere, Inc. Fibrinogen-coated microspheres
DE60032001T2 (de) * 1999-09-27 2007-05-31 Sysmex Corp. Verfahren zur stabilisierung von thrombin
US7632803B2 (en) * 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US7592304B2 (en) 1999-10-01 2009-09-22 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US20030130185A1 (en) * 2000-09-29 2003-07-10 David Bar-Or Metal-binding compounds and uses therefor
ATE260120T1 (de) * 1999-10-12 2004-03-15 Daiichi Suntory Pharma Co Ltd Arzneimittel zur oralen verabreichung
DE10012732A1 (de) 2000-03-18 2001-09-20 Aventis Behring Gmbh Thrombin-Zubereitungen und Verfahren zu ihrer Herstellung
WO2003007686A2 (en) * 2001-07-19 2003-01-30 Dmi Biosciences, Inc. Use of copper chelators to inhibit the inactivation of protein c
US7923431B2 (en) 2001-12-21 2011-04-12 Ferrosan Medical Devices A/S Haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis
EP1573295A2 (en) 2002-12-11 2005-09-14 Ferrosan A/S Gelatine-based materials as swabs
US8834864B2 (en) * 2003-06-05 2014-09-16 Baxter International Inc. Methods for repairing and regenerating human dura mater
US7927626B2 (en) * 2003-08-07 2011-04-19 Ethicon, Inc. Process of making flowable hemostatic compositions and devices containing such compositions
JP4740532B2 (ja) * 2003-09-30 2011-08-03 雪印乳業株式会社 骨形成促進及び骨吸収抑制剤
NZ545953A (en) * 2003-09-30 2010-09-30 Snow Brand Milk Products Co Ltd Agent for promoting osteogenesis and/or inhibiting bone resorption
EP1713521B1 (en) 2004-01-30 2010-07-28 Ferrosan A/S Haemostatic sprays and compositions
ES2395466T3 (es) * 2004-06-22 2013-02-12 Zymogenetics, Inc. Composiciones de trombina
RU2369408C2 (ru) 2004-07-09 2009-10-10 Ферросан А/С Гемостатическая композиция, включающая гиалуроновую кислоту
ES2226587B1 (es) * 2004-10-22 2005-12-16 Probitas Pharma, S.A. Composicion de trombina estable.
CN101454030B (zh) * 2006-05-31 2013-06-26 巴克斯特国际公司 用于脊柱外科手术中定向细胞向内生长和控制组织再生的方法
RU2468032C2 (ru) * 2006-06-26 2012-11-27 Омрикс Биофармасьютикалс Инк. Способ очистки раствора тромбина от инфекционных частиц
TWI436793B (zh) * 2006-08-02 2014-05-11 Baxter Int 快速作用之乾密封膠及其使用和製造方法
EP2214734B1 (en) 2007-10-30 2017-12-13 Baxter International Inc. Use of a regenerative biofunctional collagen biomatrix for treating visceral or parietal defects
EP2259803B2 (en) 2008-02-29 2019-03-13 Ferrosan Medical Devices A/S Device for promotion of hemostasis and/or wound healing
CN102105141B (zh) * 2008-04-16 2015-06-24 一般财团法人化学及血清疗法研究所 保持有凝血酶的生物可吸收性片制剂的制造方法
US9039783B2 (en) * 2009-05-18 2015-05-26 Baxter International, Inc. Method for the improvement of mesh implant biocompatibility
PL2442835T3 (pl) 2009-06-16 2015-07-31 Baxter Int Gąbka hemostatyczna
WO2011079336A1 (en) 2009-12-16 2011-07-07 Baxter International Inc. Hemostatic sponge
SA111320355B1 (ar) 2010-04-07 2015-01-08 Baxter Heathcare S A إسفنجة لايقاف النزف
CN103037845B (zh) 2010-06-01 2015-11-25 巴克斯特国际公司 用于制备干燥、稳定的止血组合物的方法
KR101814841B1 (ko) 2010-06-01 2018-01-03 백스터 인터내셔널 인코포레이티드 건조 및 안정한 지혈 조성물의 제조 방법
BR112012030457B1 (pt) 2010-06-01 2021-03-09 Baxter International Inc. processo para fabricar uma composição hemostática seca e estável, recipiente acabado final, método para prover uma composição hemostática pronta para uso, e, kit para administrar uma composição hemostática
AU2012318257B2 (en) 2011-10-11 2015-10-01 Baxter Healthcare S.A. Hemostatic compositions
US20130090291A1 (en) 2011-10-11 2013-04-11 Baxter Healthcare S.A. Hemostatic compositions
UY34414A (es) 2011-10-27 2013-04-30 Baxter Int Composiciones hemostáticas
RU2657955C2 (ru) 2012-03-06 2018-06-18 Ферросан Медикал Дивайсиз А/С Контейнер под давлением, содержащий гемостатическую пасту
JP6394916B2 (ja) 2012-06-12 2018-09-26 フェロサン メディカル デバイシーズ エイ／エス 乾燥止血組成物
US9724078B2 (en) 2013-06-21 2017-08-08 Ferrosan Medical Devices A/S Vacuum expanded dry composition and syringe for retaining same
CA2928963C (en) 2013-12-11 2020-10-27 Ferrosan Medical Devices A/S Dry composition comprising an extrusion enhancer
CA2960309A1 (en) 2014-10-13 2016-04-21 Ferrosan Medical Devices A/S Dry composition for use in haemostasis and wound healing
JP6747650B2 (ja) 2014-12-24 2020-08-26 フェロサン メディカル デバイシーズ エイ／エス 第１の物質と第２の物質を保持し混合するためのシリンジ
BR112017027695A2 (pt) 2015-07-03 2018-09-04 Ferrosan Medical Devices As seringa para retenção e mistura de primeira e segunda substâncias
CN112368028A (zh) 2018-05-09 2021-02-12 弗罗桑医疗设备公司 用于制备止血组合物的方法
JP2022527136A (ja) * 2019-04-12 2022-05-30 アファームド ファーマ，エルエルシー 酢酸ルサラチド組成物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2433299A (en) * 1944-01-22 1947-12-23 Parke Davis & Co Blood coagulant and method of preserving same
CH264752A (de) * 1947-06-03 1949-10-31 Hoffmann La Roche Verfahren zur Herstellung von Trägern für Arzneimittel.
DE1517787A1 (de) * 1965-12-06 1970-01-29 Takeda Chemical Industries Ltd Enzympraeparat und Verfahren zu seiner Herstellung
DE2916711A1 (de) * 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
US4363319A (en) * 1980-06-30 1982-12-14 Applied Medical Devices, Inc. Ready-to-use bandage incorporating a coagulant composition and method of preparing same
US4495278A (en) * 1981-04-27 1985-01-22 Baxter Travenol Laboratories, Inc. Process for making novel blood clotting enzyme compositions
ATE20824T1 (de) * 1981-06-25 1986-08-15 Serapharm Gmbh & Co Kg Angereichertes plasmaderivat zur unterstuetzung von wundverschluss und wundheilung.
US4563351A (en) * 1983-08-01 1986-01-07 Forsyth Dental Infirmary For Children Self-gelling therapeutic compositions for topical application
NO852655L (no) * 1985-06-05 1986-12-08 Bio Data Corp Fremgangsmaate ved fremstilling av koaguleringsreagens for blodplasma i mikrokonsentrert tablettform.
US4696812A (en) * 1985-10-28 1987-09-29 Warner-Lambert Company Thrombin preparations
JPS63243032A (ja) * 1987-03-27 1988-10-07 Green Cross Corp:The トロンビンの加熱処理方法
JPH0193536A (ja) 1987-10-01 1989-04-12 Green Cross Corp:The 経口用トロンビン製剤
JP2847160B2 (ja) 1987-11-04 1999-01-13 吉富製薬株式会社 トロンビン含有医薬組成物
US4923813A (en) * 1988-01-15 1990-05-08 American Health Foundation Monoclonal antibody-based immunoassay for cyclic DNA adducts resulting from exposure to crotonaldehyde or acrolein
JPH02218618A (ja) * 1989-02-21 1990-08-31 Green Cross Corp:The トロンビン粉末製剤

Also Published As

Publication number Publication date
DE69106549T2 (de) 1995-06-22
US5149540A (en) 1992-09-22
JPH03255035A (ja) 1991-11-13
CA2037325A1 (en) 1991-09-02
EP0444692A1 (en) 1991-09-04
AU643753B2 (en) 1993-11-25
DK0444692T3 (da) 1995-03-20
ATE116858T1 (de) 1995-01-15
DE69106549D1 (de) 1995-02-23
AU7199291A (en) 1991-09-05
JPH0813750B2 (ja) 1996-02-14
EP0444692B1 (en) 1995-01-11

Similar Documents

Publication Publication Date Title
ES2069761T3 (es) Composicion de trombina para la administracion oral.
DK20290A (da) Formuleringer med forsinket afgivelse
DK98088D0 (da) Farmaceutisk formulering med forsinket frigivelse af den aktive bestanddel
DK445687D0 (da) Bloed, sukkerfri, luftig konfekturesammensaetning
NO863061D0 (no) Fremgangsmaate for fremstilling av fysiologisk aktive fenoksyeddiksyrederivater.
IT1177152B (it) Procedimento e composizione per la preparazione di prodotti farmaceutici ad azione prolungata controllata per la somministrazione orale
DK203787A (da) Praeparat til nasal administrering
DK31088D0 (da) Blodkoaguleringsnedsaettende peptidderivater
IT1246188B (it) Procedimento per la preparazione di composizioni farmaceutiche aventi aumentata velocita' di dissoluzione della sostanza attiva e composizioni ottenute.
ATE58292T1 (de) L-dopa enthaltendes arzneimittel.
NO893270L (no) Fremgangsmaate for fremstilling av terapeutisk aktive tetrahydropyridineddiksyrederivater.
NO871295D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater.
PT615754E (pt) Formas solidas de administracao oral de libertacao controlada flupertina
SE8804628D0 (sv) New compounds
DK585889D0 (da) Farmaceutisk praeparat
NO870049D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater.
NO893142D0 (no) Fremgangsmaate for preservering av oftalmologiske opploesninger og sammensetninger for formaalet.
PH27446A (en) Compound with gastric acid inhibitory effect
IT8621097A1 (it) Derivato di timo attivo per via orale, procedimenti per la sua preparazione e relative composizioni farmaceutiche
ATE145333T1 (de) Hirudin enthaltende orale arzneimittel
ATE132877T1 (de) Emulgatorfreie emulsionspolymere in pharmazeutischen zubereitungen mit verzögerter wirkstofffreigabe und ihre herstellung
IT1136652B (it) Compesizione farmaceutica di fosfomicina in compresse da succhiare
ITMI913248A1 (it) Composizioni terapeutiche adatte per la somministrazione orale contenenti come principio attivo uno o piu' tioesteri del glutatione e procedimento per la preparazione dei suddetti principi attivi
ITMI913461A0 (it) Composizioni terapeutiche adatte per la somministrazione rettale contenenti come principio attivo uno o piu' tioesteri del glutatione
IL81926A0 (en) Pharmaceutical compositions for the oral administration of active proteins

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 444692

Country of ref document: ES